Year: 2024

Press ReleaseNicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 TrialAn adaptive design is a useful clinical trial design tool which allowed identification of the optimal dose of NCX 470 in the Mont Blanc trial, the first Phase 3 trial of NCX 470 Both doses of NCX 470 ophthalmic solution tested, 0.065% and 0.1%, lowered intraocular pressure more than the comparator, latanoprost 0.005% ophthalmic solution The 0.1% NCX 470 concentration was chosen for the remainder of the Mont Blanc trial and the ongoing Denali trial based on a greater intraocular pressure reduction compared to the 0.065% concentration and a good safety profileNovember 18, 2024 – release at 7:30 am CETSophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company,...

Sampo plc, stock exchange release, 19 November 2024 at 8:30 am EET Sampo plc’s share buybacks 18 November 2024 On 18 November 2024, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  5,039 40.05 AQEU          40,212 40.06 CEUX  933 40.07 TQEX  47,821 40.05 XHELTOTAL 94,005 40.05  *rounded to two decimals                 On 17 June 2024, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. On 16 September 2024, the Board of Directors...

Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activity A greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care alone Systemic Lupus Erythematosus is a chronic, debilitating autoimmune disease affecting multiple organ systems, primarily in women, for whom there is a significant need for additional treatment optionsBRUSSELS, Belgium and CAMBRIDGE, Mass., Nov. 19, 2024 (GLOBE NEWSWIRE) — UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP),...

REGULATED INFORMATIONNovember 19, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024 The board of directors of the Company is pleased to invite its securities holders to attend the special shareholders’ meeting of the Company, to be held on Thursday, December 19, 2024 at 3:00 p.m. CET at the Company’s seat, or at such other place as will be indicated prior to such time. The Company will also set up a video conference to allow holders of securities of the Company who have duly registered for the special shareholders’ meeting to follow the meeting remotely and ask questions, as the case may be in writing, during the meeting....

MIRAMAR, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) — HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 6,717,000 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced above market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an aggregate of 6,717,000 shares of common stock. The combined effective offering price for each share of common stock (or pre-funded warrant in...

TORONTO, Nov. 18, 2024 (GLOBE NEWSWIRE) — Partners Value Investments Inc. (the “Company”, TSX: PVF.WT, PVF.PR.V) announced today its financial results for the nine months ended September 30, 2024. All amounts are stated in U.S. dollars. The Company recorded net loss of $1.2 billion for the three months ended September 30, 2024, compared to a net income of $72.1 million in the prior year quarter. The decrease in income was primarily due to current period remeasurement losses of $1.1 billion associated with the retractable shares, compared to remeasurement gains of $35.0 million in the prior year quarter. The Company’s retractable common shares are classified as liabilities due to their cash retraction feature. The remeasurement gains or losses in a given period are driven by the respective appreciation or depreciation of the Partners...